To: Stock
Exchange
|
For
immediate release:
|
|
28 November
2024
|
CT Private Equity Trust
PLC
Quarterly results for the three
months ended 30 September 2024 (unaudited)
·
Net asset value of 680.03p per Ordinary Share
reflecting a total return for the three months of -1.0 per cent for
the Ordinary Shares
·
Share price total return for the three-month
period of 6.6%.
·
Total quarterly dividends of 21.03p per Ordinary
Share year to date representing an increase of 3.3 per cent from
the same period last year.
o Quarterly dividend of 7.01p paid on 31 July 2024
o Quarterly dividend of 7.01p paid on 31 October 2024
o Quarterly dividend of 7.01p to be paid on 31 January
2025
·
Dividend yield of 6.2 per cent based on the period
end share price (1).
·
As at 30 September 2024 net debt was £70.3 million
equivalent to a gearing level of 12.6%.
·
Realisations year to date of £94.5 million.
This represents an increase of 75.3% in comparison to the same
period last year.
(1) Calculated as dividends of 7.01p paid on 30 April 2024, 7.01p
paid on 31 July 2024, 7.01p paid on 31 October 2024 and 7.01p
payable on 31 January 2025, divided by the Company's share price of
455.00p as at 30 September 2024.
Manager's Review
Introduction
As at 30 September 2024 the net
assets of the Company were £486.2 million giving a NAV per share of
680.03p, which taking into account the dividend of 7.01p per share
paid on 31 July 2024, gives a total return for the third quarter of
-1.0%. The total return for the year to date is -0.2%. In the third
quarter, there was an adverse influence from currency of around
1.5% as both the dollar and euro were weak against sterling.
Underlying valuations are slightly ahead for the year to date. It
is worth bearing in mind that the September valuation is largely
based on June marks with only around 8% of September valuations
included.
The Company had net debt of £70.3
million at 30 September 2024. Outstanding undrawn commitments were
£192.0 million of which £21.5 million were to funds where the
investment period has expired.
The dividend for the quarter will be
unchanged at 7.01p per share, payable on 31 January 2025 to
shareholders on the register on 3 January 2025 with an ex-dividend
date of 2 January 2025.
New Investments
There was only one new investment in
the quarter with £5 million committed to Inflexion Enterprise Fund
VI, the latest in a series of Inflexion funds focusing on lower
mid-market buyouts in the UK and Western Europe.
There were some small follow-on
investments in our co-investment portfolio which occurred just
after the quarter end. £0.9 million was added to the digital
payments merchant acquirer Aurora Payment Solutions and £0.5
million was added to police and local offence processing software
provider Polaris Software (formerly StarTraq).
The funds in the portfolio made a
few notable new investments this quarter.
HG Saturn 3 called £1.7 million for
three investments in Visma (£0.8 million, European and LatAm
mission-critical cloud software), Iris (£0.7 million, tax and
accounting software) and GGW (£0.1 million, German insurance
brokerage and MGA platform).
Med Platform II invested £0.8
million in two companies; Jeisys, a South Korean based producer of
energy based medical devices and Irrimax Corporation, a US based
wound irrigation and anti-microbial solutions provider. Volpi
invested £0.8 million in Yaveon (ERP software and consulting
provider) and Xalient (software and cybersecurity services
provider) and Summa III called £0.5 million for Axion
(bioelectronic array and live-cell imaging instruments). Inflexion
called £0.5 million for a carve-out of the healthcare division from
AIM-listed GlobalData and £0.7 million for DwF, the global legal
and professional services firm.
In total the third quarter was
fairly quiet for new investments with drawdowns totalling just £9.3
million. Total new investment so far this year amounts to £45.2
million which is down on last year by more than 50%.
Realisations
There were several good exits in the
quarter, a number of which have already been reported.
The largest exit was the sale of the
Kester led co-investment in ATEC. The combined proceeds from both
the co-investment, the proportion held in the GCP Europe II fund
and the proportion held through The Aurora Fund position was £18.5
million. This represented an excellent return over the
seven-year hold. ATEC is an insurance broker and managing general
agent covering caravans, small boats and beach huts. It has grown
profits by almost fourfold over the holding period.
The Buckthorn-led energy services
company Coretrax was fully realised during the quarter with the
shares with which its acquirer, Expro, bought the company being
sold down successfully realising £10.3 million bringing the total
consideration to £13.7 million which at 1.7x cost and 11% IRR is a
fair result given the volatile conditions in its sector since the
investment was made nearly six years ago.
From the funds portfolio there were
some excellent further exits.
Summa II sold Olink to Thermo Fisher
raising £3.6 million. Olink has developed a technology for
analysing proteins which is used in human protein biomarker
research. The investment achieved a highly creditable 10x cost and
an IRR of 67%.
Italian fund Nem Imprese made its
final exit with the sale of business processing and outsourcing
company Kauri yielding £2.1 million.
UK fund RJD Fund III exited
veterinary education company Improve International returning £1.4
million which represents 3.3x cost and an IRR of 49%.
Inflexion Enterprise Fund IV sold
pet supplements company Lintbells yielding £1.0 million (5.5x and
an IRR of 34%).
Astorg VI has made the exits of two
companies returning a combined £0.9 million. Acturis, a provider of
software for the insurance sector (2.6x, 21% IRR) and Audiotonix
the designer and manufacturer of premium professional audio
equipment and software (2.6x, 25% IRR). In the case of Acturis,
Astorg remains invested in the company through its later
funds.
In Finland Vaaka II has achieved a
remarkable exit of Cloudpermit, a software company serving building
permit and land management functions mainly for municipalities.
This has been driven by a shift away from predominantly paper-based
process to a digital one, increasing the efficiency of the
permitting process. £0.7 million was returned which represents 8.7x
cost and 53% IRR.
As can be noted from the above there
remains a strong technology theme in the companies achieving strong
exits across the portfolio.
Total realisations in the quarter
were £42.2 million which brings the year-to-date total to £94.5
million, which compares with £61.8 million for the whole of
2023.
Valuation movements
The overall valuation movement this
quarter is slightly negative. Before taking account of currency
movements the underlying portfolio is up by 1.2%. The weakness of
both the euro (-1.9%) and the dollar (-5.8%) has resulted in a FX
movement in the portfolio of -£10.7 million over the quarter, which
has more than offset the gains.
The most notable movements in the
quarter are as follows. ATEC (+£1.8 million) reflecting its sale at
above the latest valuation, Weird Fish (+£1.8 million) due to
improved trading, Educa Edtech (+£1.6 million) also trading well
and Ambio (+£1.0 million) based on an improved sales multiple.
Several of the funds are also up, led by GCP Europe II which holds
ATEC (+£0.7 million). Avallon III is up by £0.6 million due to pet
food company MPPK trading well. RJD III (+£0.6 million) is up
reflecting the sale of Improve International above the holding
value as noted above.
On the negative side there were a
few actual downgrades of note. Breeze Group (formerly Contained Air
Solutions) was down by £1.0 million and Bulgarian bike assembler
Leader96 was down by £1.5 million. Breeze is in reasonable shape
having just completed some useful new additions, with the UK add-on
Amercare trading very well in the year to date. Leader96 faces a
challenging market which is destocking; however, an agreement with
the banks has been reached, part of the old factory has been
sold and reinforcement of management is under way. Most of
the fund positions were slightly up or slightly down, cancelling
out one another.
Financing
The Company had net debt at the end
of September of £70.3 million which is well down from £91.3 million
at June. This represents gearing of 12.6%. Approximately half of
the Company's borrowing facilities are unused with plenty of
headroom.
Outlook
The private equity market
internationally has been going through a period of adjustment for
most of the last two years. Much higher interest rates and external
pressures such as inflation and world events have impacted the
dealmaking environment in 2023 and the first half of 2024. The
latest trend is more clearly upwards and growth in deal volume and
value over 2023 is expected for 2024 as a whole. The clear upswing
in realisations across our portfolio confirms this trend. As always
business and consumer confidence is an important factor. In many
markets, including the US and the UK, 2024 has been an election
year and with each of these behind us there is clear scope for a
better trend to take root.
Private equity is the most
interventionist of asset classes where managers can make
adjustments as the world around them changes and there is a very
strong record of making good returns over the long term
irrespective of the background conditions. As we approach the end
of 2024, the mood of our investment partners is considerably better
than it was earlier in the year and both statistical and anecdotal
evidence suggests good grounds for optimism as we finish 2024 and
enter 2025. We remain confident that we will continue to build
value for Shareholders over the short and longer term.
Hamish Mair
Investment Manager
Columbia Threadneedle Investment
Business Limited
Portfolio Summary
Portfolio Distribution at 30
September 2024
|
% of
Total
30
September 2024
|
% of
Total
31
December 2023
|
Buyout Funds - Pan
European*
|
11.2
|
10.5
|
Buyout Funds - UK
|
18.7
|
16.2
|
Buyout Funds - Continental
Europe†
|
16.7
|
18.2
|
Secondary Funds
|
0.1
|
0.1
|
Private Equity Funds -
USA
|
4.4
|
5.0
|
Private Equity Funds -
Global
|
2.3
|
1.7
|
Venture Capital Funds
|
4.6
|
3.7
|
Direct
Investments/Co-investments
|
42.0
|
44.6
|
|
100.0
|
100.0
|
* Europe including the
UK.
† Europe excluding the
UK.
|
|
|
|
|
|
Ten
Largest Holdings
As
at 30 September 2024
|
Total
Valuation £'000
|
% of Total Portfolio
|
Inflexion Strategic
Partners
|
16,342
|
2.9
|
Sigma
|
14,972
|
2.7
|
August Equity Partners V
|
11,363
|
2.0
|
Weird Fish
|
11,313
|
2.0
|
Aliante Equity 3
|
11,262
|
2.0
|
TWMA
|
10,847
|
1.9
|
San Siro
|
10,127
|
1.8
|
Axiom 1
|
9,942
|
1.8
|
Stirling Square Capital
II
|
9,363
|
1.7
|
SEP V
|
9,110
|
1.6
|
114,641
|
20.4
|
Portfolio Holdings
|
Investment
|
Geographic Focus
|
Total
Valuation
£'000
|
% of Total
Portfolio
|
|
|
Buyout Funds - Pan European
|
|
|
|
|
|
Stirling Square Capital
II
|
Europe
|
9,363
|
1.7
|
|
|
Apposite Healthcare III
|
Europe
|
9,076
|
1.6
|
|
|
Apposite Healthcare II
|
Europe
|
8,880
|
1.6
|
|
|
F&C European Capital
Partners
|
Europe
|
8,784
|
1.6
|
|
|
MED II
|
Western Europe
|
3,286
|
0.6
|
|
|
Agilitas 2015 Fund
|
Northern Europe
|
2,719
|
0.5
|
|
|
Magnesium Capital 1
|
Europe
|
2,392
|
0.4
|
|
|
Astorg VI
|
Western Europe
|
2,231
|
0.4
|
|
|
Volpi III
|
Northern Europe
|
2,080
|
0.4
|
|
|
Verdane XI
|
Northern Europe
|
2,041
|
0.4
|
|
|
MED Platform II
|
Global
|
1,700
|
0.3
|
|
|
Wisequity VI
|
Italy
|
1,644
|
0.3
|
|
|
Summa III
|
Northern Europe
|
1,611
|
0.3
|
|
|
Agilitas 2020 Fund
|
Europe
|
1,261
|
0.2
|
|
|
TDR Capital II
|
Western Europe
|
1,065
|
0.2
|
|
|
ARCHIMED MED III
|
Global
|
1,061
|
0.2
|
|
|
Verdane Edda III
|
Northern Europe
|
943
|
0.2
|
|
|
TDR II Annex Fund
|
Western Europe
|
921
|
0.1
|
|
|
KKA II
|
Europe
|
908
|
0.1
|
|
|
Inflexion Partnership III
|
Europe
|
540
|
0.1
|
|
|
Agilitas 2024 HIF
|
Europe
|
98
|
-
|
|
|
Volpi Capital
|
Northern Europe
|
38
|
-
|
|
|
Total Buyout Funds - Pan
European
|
|
62,642
|
11.2
|
|
|
Buyout Funds - UK
|
|
|
|
|
|
Inflexion Strategic
Partners
|
United Kingdom
|
16,342
|
2.9
|
|
|
August Equity Partners V
|
United Kingdom
|
11,363
|
2.0
|
|
|
Axiom 1
|
United Kingdom
|
9,942
|
1.8
|
|
|
Inflexion Supplemental V
|
United Kingdom
|
8,543
|
1.5
|
|
|
Inflexion Buyout Fund V
|
United Kingdom
|
6,093
|
1.1
|
|
|
Apiary Capital Partners I
|
United Kingdom
|
5,116
|
0.9
|
|
|
Inflexion Buyout Fund VI
|
United Kingdom
|
4,811
|
0.9
|
|
|
August Equity Partners IV
|
United Kingdom
|
4,551
|
0.8
|
|
|
Kester Capital II
|
United Kingdom
|
3,854
|
0.7
|
|
|
FPE Fund II
|
United Kingdom
|
3,846
|
0.7
|
|
|
Piper Private Equity VI
|
United Kingdom
|
3,803
|
0.7
|
|
|
FPE Fund III
|
United Kingdom
|
3,725
|
0.7
|
|
|
Inflexion Partnership Capital
II
|
United Kingdom
|
3,610
|
0.6
|
|
|
Inflexion Enterprise Fund
V
|
United Kingdom
|
3,206
|
0.6
|
|
|
Corran Environmental II
|
United Kingdom
|
2,747
|
0.5
|
|
|
Inflexion Buyout Fund IV
|
United Kingdom
|
2,481
|
0.4
|
|
|
Piper Private Equity VII
|
United Kingdom
|
2,446
|
0.4
|
|
|
Inflexion Supplemental IV
|
United Kingdom
|
1,457
|
0.3
|
|
|
Inflexion Enterprise Fund
IV
|
United Kingdom
|
1,439
|
0.3
|
|
|
Inflexion Partnership Capital
I
|
United Kingdom
|
1,078
|
0.2
|
|
|
Primary Capital IV
|
United Kingdom
|
1,067
|
0.2
|
|
|
Horizon Capital 2013
|
United Kingdom
|
1,067
|
0.2
|
|
|
Kester Capital III
|
United Kingdom
|
906
|
0.2
|
|
|
RJD Private Equity Fund
III
|
United Kingdom
|
404
|
0.1
|
|
|
Piper Private Equity V
|
United Kingdom
|
227
|
-
|
|
|
GCP Europe II
|
United Kingdom
|
127
|
-
|
|
|
August Equity Partners VI
|
United Kingdom
|
46
|
-
|
|
|
Dunedin Buyout Fund II
|
United Kingdom
|
17
|
-
|
|
|
Total Buyout Funds - UK
|
|
104,314
|
18.7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investment
|
Geographic Focus
|
Total
Valuation
£'000
|
% of Total
Portfolio
|
|
|
Buyout Funds - Continental Europe
|
|
|
|
|
|
Aliante Equity 3
|
Italy
|
11,262
|
2.0
|
|
|
Bencis V
|
Benelux
|
6,693
|
1.2
|
|
|
Avallon MBO Fund III
|
Poland
|
6,246
|
1.1
|
|
|
DBAG VIII
|
DACH
|
5,814
|
1.0
|
|
|
DBAG VII
|
DACH
|
5,603
|
1.0
|
|
|
Vaaka III
|
Finland
|
5,234
|
0.9
|
|
|
Chequers Capital XVII
|
France
|
4,932
|
0.9
|
|
|
Capvis III CV
|
DACH
|
4,931
|
0.9
|
|
|
Verdane Edda
|
Nordic
|
4,163
|
0.8
|
|
|
Montefiore V
|
France
|
4,118
|
0.7
|
|
|
Procuritas VI
|
Nordic
|
3,799
|
0.7
|
|
|
ARX CEE IV
|
Eastern Europe
|
3,030
|
0.5
|
|
|
Corpfin V
|
Spain
|
3,015
|
0.5
|
|
|
Procuritas VII
|
Nordic
|
2,720
|
0.5
|
|
|
Procuritas Capital IV
|
Nordic
|
2,472
|
0.4
|
|
|
Italian Portfolio
|
Italy
|
2,399
|
0.4
|
|
|
Capvis IV
|
DACH
|
2,092
|
0.4
|
|
|
Vaaka IV
|
Finland
|
2,073
|
0.4
|
|
|
Montefiore IV
|
France
|
1,840
|
0.3
|
|
|
Aurica IV
|
Spain
|
1,514
|
0.3
|
|
|
Summa I
|
Nordic
|
1,367
|
0.3
|
|
|
Summa II
|
Nordic
|
1,329
|
0.2
|
|
|
Portobello Fund III
|
Spain
|
1,204
|
0.2
|
|
|
Corpfin Capital Fund IV
|
Spain
|
1,065
|
0.2
|
|
|
DBAG VIIB
|
DACH
|
1,038
|
0.2
|
|
|
DBAG VIIIB
|
DACH
|
885
|
0.2
|
|
|
Chequers Capital XVI
|
France
|
675
|
0.1
|
|
|
DBAG Fund VI
|
DACH
|
583
|
0.1
|
|
|
PineBridge New Europe II
|
Eastern Europe
|
308
|
0.1
|
|
|
Ciclad 5
|
France
|
297
|
0.1
|
|
|
Procuritas Capital V
|
Nordic
|
261
|
0.1
|
|
|
Vaaka II
|
Finland
|
121
|
-
|
|
|
Montefiore Expansion
|
France
|
106
|
-
|
|
|
Gilde Buyout Fund III
|
Benelux
|
89
|
-
|
|
|
N+1 Private Equity Fund
II
|
Iberia
|
87
|
-
|
|
|
Capvis III
|
DACH
|
50
|
-
|
|
|
DBAG Fund V
|
DACH
|
5
|
-
|
|
|
Herkules Private Equity
III
|
Nordic
|
4
|
-
|
|
|
Total Buyout Funds - Continental
Europe
|
|
93,424
|
16.7
|
|
|
|
|
|
|
|
|
|
|
|
|
Secondary Funds
|
|
|
|
|
|
The Aurora Fund
|
Europe
|
330
|
0.1
|
|
|
Total Secondary Funds
|
|
330
|
0.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investment
|
Geographic Focus
|
Total
Valuation
£'000
|
% of Total
Portfolio
|
|
|
|
|
|
|
|
|
|
|
|
Total Private Equity Funds - USA
Blue Point Capital IV
|
North America
|
7,329
|
1.3
|
Camden Partners IV
|
United States
|
3,006
|
0.5
|
Level 5 Fund II
|
United States
|
2,734
|
0.5
|
Purpose Brands (Level 5)
|
United States
|
2,642
|
0.5
|
Graycliff IV
|
North America
|
2,594
|
0.5
|
Blue Point Capital III
|
North America
|
1,946
|
0.3
|
Stellex Capital Partners
|
North America
|
1,701
|
0.3
|
MidOcean VI
|
United States
|
1,563
|
0.3
|
Graycliff III
|
United States
|
980
|
0.2
|
Blue Point Capital II
|
North America
|
150
|
-
|
Total Private Equity Funds -
USA
|
|
24,645
|
4.4
|
|
|
|
|
|
|
|
|
Private Equity Funds - Global
|
|
|
|
Corsair VI
|
Global
|
6,528
|
1.2
|
Hg Saturn 3
|
Global
|
4,363
|
0.8
|
PineBridge GEM II
|
Global
|
610
|
0.1
|
Hg Mercury 4
|
Global
|
508
|
0.1
|
F&C Climate Opportunity
Partners
|
Global
|
459
|
0.1
|
AIF Capital Asia III
|
Asia
|
108
|
-
|
PineBridge Latin America
II
|
South America
|
55
|
-
|
Warburg Pincus IX
|
Global
|
9
|
-
|
Total Private Equity Funds -
Global
|
|
12,640
|
2.3
|
Venture Capital Funds
|
|
|
|
SEP V
|
United Kingdom
|
9,110
|
1.6
|
MVM V
|
Global
|
3,790
|
0.7
|
SEP VI
|
Europe
|
3,161
|
0.6
|
Kurma Biofund II
|
Europe
|
2,786
|
0.5
|
MVM VI
|
Global
|
2,653
|
0.5
|
Northern Gritstone
|
United Kingdom
|
2,000
|
0.4
|
SEP IV
|
United Kingdom
|
1,113
|
0.2
|
Pentech Fund II
|
United Kingdom
|
385
|
0.1
|
SEP II
|
United Kingdom
|
260
|
-
|
Life Sciences Partners III
|
Western Europe
|
248
|
-
|
SEP III
|
United Kingdom
|
60
|
-
|
Environmental Technologies
Fund
|
Europe
|
56
|
-
|
Total Venture Capital
Funds
|
|
25,622
|
4.6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investment
|
Geographic Focus
|
Total
Valuation
£'000
|
% of Total
Portfolio
|
Direct Investments/Co-investments
|
|
|
|
Sigma
|
United States
|
14,972
|
2.7
|
Weird Fish
|
United Kingdom
|
11,313
|
2.0
|
TWMA
|
United Kingdom
|
10,847
|
1.9
|
San Siro
|
Italy
|
10,127
|
1.8
|
Aurora Payment Solutions
|
United States
|
9,005
|
1.6
|
Utimaco
|
DACH
|
8,852
|
1.6
|
Cyclomedia
|
Netherlands
|
8,751
|
1.6
|
Cyberhawk
|
United Kingdom
|
8,530
|
1.5
|
Breeze Group (CAS)
|
United Kingdom
|
8,270
|
1.5
|
Amethyst Radiotherapy
|
Europe
|
8,118
|
1.5
|
Asbury Carbons
|
North America
|
6,831
|
1.2
|
Velos IoT (JT IoT)
|
United Kingdom
|
6,741
|
1.2
|
Habitus
|
Denmark
|
6,739
|
1.2
|
Prollenium
|
North America
|
6,227
|
1.1
|
CARDO Group
|
United Kingdom
|
6,204
|
1.1
|
Swanton
|
United Kingdom
|
6,199
|
1.1
|
Family First
|
United Kingdom
|
5,968
|
1.1
|
Orbis
|
United Kingdom
|
5,799
|
1.0
|
Cybit (Perfect Image)
|
United Kingdom
|
5,176
|
0.9
|
Rosa Mexicano
|
United States
|
5,103
|
0.9
|
Polaris Software
(StarTraq)
|
United Kingdom
|
4,840
|
0.9
|
AccuVein
|
United States
|
4,634
|
0.8
|
Educa Edtech
|
Spain
|
4,583
|
0.8
|
123Dentist
|
Canada
|
4,533
|
0.8
|
Braincube
|
France
|
4,477
|
0.8
|
MedSpa Partners
|
Canada
|
4,201
|
0.8
|
Dotmatics
|
United Kingdom
|
4,043
|
0.7
|
1Med
|
Switzerland
|
3,933
|
0.7
|
LeadVenture
|
United States
|
3,913
|
0.7
|
Walkers Transport
|
United Kingdom
|
3,729
|
0.7
|
Vero Biotech
|
United States
|
2,956
|
0.5
|
PathFactory
|
Canada
|
2,934
|
0.5
|
Omlet
|
United Kingdom
|
2,832
|
0.5
|
Collingwood Insurance
Group
|
United Kingdom
|
2,671
|
0.5
|
AccountsIQ
|
Ireland
|
2,530
|
0.5
|
Agilico (DMC Canotec)
|
United Kingdom
|
2,516
|
0.5
|
GT Medical
|
United States
|
2,236
|
0.4
|
Neurolens
|
United States
|
2,215
|
0.4
|
Ambio Holdings
|
United States
|
2,041
|
0.4
|
Alessa (Tier1 CRM)
|
Canada
|
1,947
|
0.4
|
OneTouch
|
United Kingdom
|
1,861
|
0.3
|
Bomaki
|
Italy
|
1,466
|
0.3
|
Rephine
|
United Kingdom
|
1,360
|
0.2
|
Avalon
|
United Kingdom
|
1,234
|
0.2
|
Leader96
|
Bulgaria
|
704
|
0.1
|
Jollyes
|
United Kingdom
|
397
|
0.1
|
TDR Algeco/Scotsman
|
Europe
|
226
|
-
|
Coretrax
|
United Kingdom
|
94
|
-
|
Total Direct
Investments/Co-investments
|
|
234,878
|
42.0
|
Total Portfolio
|
|
558,495
|
100.0
|
CT PRIVATE EQUITY TRUST
PLC
Statement of Comprehensive
Income for the
nine months ended 30
September 2024 (unaudited)
|
|
|
Revenue
£'000
|
Capital
£'000
|
Total
£'000
|
Income
|
|
|
|
Gains on investments held at fair
value
|
-
|
83
|
83
|
Exchange gains
|
-
|
4,443
|
4,443
|
Investment income
|
2,110
|
-
|
2,110
|
Other income
|
794
|
-
|
794
|
Total income
|
2,904
|
4,526
|
7,430
|
|
|
|
|
Expenditure
|
|
|
|
Investment management fee - basic
fee
|
(365)
|
(3,284)
|
(3,649)
|
Investment management fee -
performance fee
|
-
|
-
|
-
|
Other expenses
|
(916)
|
-
|
(916)
|
Total expenditure
|
(1,281)
|
(3,284)
|
(4,565)
|
|
|
|
|
Profit before finance costs and taxation
|
1,623
|
1,242
|
2,865
|
|
|
|
|
Finance costs
|
(679)
|
(6,115)
|
(6,794)
|
|
|
|
|
Profit/(loss) before taxation
|
944
|
(4,873)
|
(3,929)
|
|
|
|
|
Taxation
|
-
|
-
|
-
|
|
|
|
|
Profit/(loss) for period/total comprehensive
income
|
944
|
(4,873)
|
(3,929)
|
|
|
|
|
Return per Ordinary Share
|
1.31p
|
(6.77)p
|
(5.46)p
|
|
|
|
|
CT
PRIVATE EQUITY TRUST PLC
Statement of Comprehensive
Income for the
nine months ended 30
September 2023 (unaudited)
|
Revenue
£'000
|
Capital
£'000
|
Total
£'000
|
Income
|
|
|
|
Gains on investments held at fair
value
|
-
|
14,181
|
14,181
|
Exchange gains
|
-
|
759
|
759
|
Investment income
|
1,618
|
-
|
1,618
|
Other income
|
552
|
-
|
552
|
Total income
|
2,170
|
14,940
|
17,110
|
|
|
|
|
Expenditure
|
|
|
|
Investment management fee - basic
fee
|
(354)
|
(3,187)
|
(3,541)
|
Investment management fee -
performance fee
|
-
|
(5,017)
|
(5,017)
|
Other expenses
|
(816)
|
-
|
(816)
|
Total expenditure
|
(1,170)
|
(8,204)
|
(9,374)
|
|
|
|
|
Profit before finance costs and taxation
|
1,000
|
6,736
|
7,736
|
|
|
|
|
Finance costs
|
(336)
|
(3,026)
|
(3,362)
|
|
|
|
|
Profit before taxation
|
664
|
3,710
|
4,374
|
|
|
|
|
Taxation
|
-
|
-
|
-
|
|
|
|
|
Profit for period/total comprehensive income
|
664
|
3,710
|
4,374
|
|
|
|
|
Return per Ordinary Share
|
0.91p
|
5.09p
|
6.00p
|
|
|
|
|
CT PRIVATE EQUITY TRUST
PLC
Statement of Comprehensive
Income for the
year ended 31 December 2023
(audited)
|
|
|
Revenue
£'000
|
Capital
£'000
|
Total
£'000
|
Income
|
|
|
|
Gains on investments held at fair
value
|
-
|
25,226
|
25,226
|
Exchange gains
|
-
|
863
|
863
|
Investment income
|
2,703
|
-
|
2,703
|
Other income
|
689
|
-
|
689
|
Total income
|
3,392
|
26,089
|
29,481
|
|
|
|
|
Expenditure
|
|
|
|
Investment management fee - basic
fee
|
(474)
|
(4,263)
|
(4,737)
|
Investment management fee -
performance fee
|
-
|
(4,767)
|
(4,767)
|
Other expenses
|
(1,064)
|
-
|
(1,064)
|
Total expenditure
|
(1,538)
|
(9,030)
|
(10,568)
|
|
|
|
|
Profit before finance costs and taxation
|
1,854
|
17,059
|
18,913
|
|
|
|
|
Finance costs
|
(513)
|
(4,616)
|
(5,129)
|
|
|
|
|
Profit before taxation
|
1,341
|
12,443
|
13,784
|
|
|
|
|
Taxation
|
-
|
-
|
-
|
|
|
|
|
Profit for year/total comprehensive income
|
1,341
|
12,443
|
13,784
|
|
|
|
|
Return per Ordinary Share
|
1.84p
|
17.08p
|
18.92p
|
|
|
|
|
CT PRIVATE EQUITY TRUST
PLC
Balance Sheet
|
As at 30 September
2024
|
As at 30 September
2023
|
As at 31
December
2023
|
|
(unaudited)
|
(unaudited)
|
(audited)
|
|
£'000
|
£'000
|
£'000
|
Non-current assets
|
|
|
|
Investments at fair value through
profit or loss
|
558,495
|
589,185
|
605,603
|
|
|
|
|
Current assets
|
|
|
|
Other receivables
|
3,196
|
1,551
|
841
|
Cash and cash equivalents
|
22,678
|
3,995
|
9,879
|
|
25,874
|
5,546
|
10,720
|
|
|
|
|
Current liabilities
|
|
|
|
Other payables
|
(5,144)
|
(9,036)
|
(8,121)
|
Interest-bearing bank loan
|
(44,222)
|
(78,477)
|
(97,109)
|
|
(49,366)
|
(87,513)
|
(105,230)
|
Net
current liabilities
|
(23,492)
|
(81,967)
|
(94,510)
|
|
|
|
|
|
|
|
|
Interest-bearing bank loan
|
(48,760)
|
-
|
-
|
Net
assets
|
486,243
|
507,218
|
511,093
|
|
|
|
|
Equity
|
|
|
|
Called-up ordinary share
capital
|
739
|
739
|
739
|
Share premium account
|
2,527
|
2,527
|
2,527
|
Special distributable capital
reserve
|
3,818
|
10,026
|
9,597
|
Special distributable revenue
reserve
|
31,403
|
31,403
|
31,403
|
Capital redemption reserve
|
1,335
|
1,335
|
1,335
|
Capital reserve
|
446,421
|
461,188
|
465,492
|
Shareholders' funds
|
486,243
|
507,218
|
511,093
|
|
|
|
|
Net
asset value per Ordinary Share
|
680.03p
|
696.30p
|
702.50p
|
|
|
|
|
CT PRIVATE EQUITY TRUST
PLC
Reconciliation of Movements in
Shareholders' Funds
|
Nine months ended
30 September
2024
|
Nine months ended
30 September 2023
|
Year
ended
31 December 2023
|
|
(unaudited)
|
(unaudited)
|
(audited)
|
|
£'000
|
£'000
|
£'000
|
Opening shareholders'
funds
|
511,093
|
517,675
|
517,675
|
Buyback of ordinary
shares
|
(5,779)
|
-
|
(429)
|
(Loss)/profit for the
period/total
comprehensive income
|
(3,929)
|
4,374
|
13,784
|
Dividends paid
|
(15,142)
|
(14,831)
|
(19,937)
|
Closing shareholders'
funds
|
486,243
|
507,218
|
511,093
|
Notes (unaudited)
1. The
unaudited quarterly results have been prepared on the basis of the
accounting policies set out in the statutory accounts of the
Company for the year ended 31 December 2023. Earnings for the
nine months to 30 September 2024 should not be taken as a guide to
the results for the year to 31 December 2024.
2.
Investment management fee:
|
Nine months ended
30 September 2024
(unaudited)
|
Nine months ended
30 September 2023
(unaudited)
|
Year ended
31 December 2023
(audited)
|
|
Revenue
£'000
|
Capital
£'000
|
Total
£'000
|
Revenue
£'000
|
Capital
£'000
|
Total
£'000
|
Revenue
£'000
|
Capital
£'000
|
Total
£'000
|
|
|
|
|
|
|
|
|
|
|
Investment
management fee - basic
fee
|
365
|
3,284
|
3,649
|
354
|
3,187
|
3,541
|
474
|
4,263
|
4,737
|
Investment
management fee - performance
fee
|
-
|
-
|
-
|
-
|
5,017
|
5,017
|
-
|
4,767
|
4,767
|
|
365
|
3,284
|
3,649
|
354
|
8,204
|
8,558
|
474
|
9,030
|
9,504
|
|
|
|
|
|
|
|
|
|
|
3. Finance
costs:
|
Nine months ended
30 September 2024
(unaudited)
|
Nine months ended
30 September 2023
(unaudited)
|
Year ended
31 December 2023
(audited)
|
|
Revenue
£'000
|
Capital
£'000
|
Total
£'000
|
Revenue
£'000
|
Capital
£'000
|
Total
£'000
|
Revenue
£'000
|
Capital
£'000
|
Total
£'000
|
|
|
|
|
|
|
|
|
|
|
Interest payable on bank
loans
|
679
|
6,115
|
6,794
|
336
|
3,026
|
3,362
|
513
|
4,616
|
5,129
|
|
|
|
|
|
|
|
|
|
|
4. Returns
and net asset values
|
Nine months ended
30 September 2024
(unaudited)
|
Nine months ended
30 September 2023
(unaudited)
|
Year ended
31 December 2023
(audited)
|
The returns and net asset values
per share are based on the following figures:
|
|
|
|
Revenue Return
|
£944,000
|
£664,000
|
£1,341,000
|
Capital Return
|
£(4,873,000)
|
£3,710,000
|
£12,443,000
|
Net assets attributable to
shareholders
|
£486,243,000
|
£507,218,000
|
£511,093,000
|
Number of shares in issue at end of
period (excluding shares held in treasury)
|
71,502,938
|
72,844,938
|
72,752,938
|
Weighted average number of shares
in issue during the period
(excluding shares held in
treasury)
|
71,960,967
|
72,844,938
|
72,838,637
|
5. The
financial information for the nine months ended 30 September 2024,
which has not been audited or reviewed by the Company's auditor,
comprises non-statutory accounts within the meaning of Section 434
of the Companies Act 2006. Statutory accounts for the year
ended 31 December 2023, on which the auditor issued an unqualified
report, have been lodged with the Registrar of Companies. The
quarterly report is available on the Company's website
www.ctprivateequitytrust.com
Legal Entity Identifier:
2138009FW98WZFCGRN66
For more information, please
contact: